Xiao-Ling Li

TL;DR: In this article, the authors investigated the efficacy and safety of an erlotinib plus bevacizumab regimen in untreated patients with advanced non-small cell lung cancer (NSCLC).

TL;DR: As compared with E alone, B plus E showed superior efficacy with acceptable tolerability and could be a new standard first-line regimen in EGFR mutated NSCLC.

TL;DR: Before tyrosine kinase inhibitor (TKI) therapy can be administered in patients with advanced non‐small cell lung cancer (NSCLC), EGFR mutation testing is required, but few studies have evaluated the extent of EGFR testing in real‐world practice in China.

TL;DR: It is suggested that anlotinib is a promising treatment option for patients with relapsed SCLC who have experienced treatment failure with two lines of chemotherapy with favorable safety profile.

TL;DR: ZL-2306-005 as discussed by the authors is a randomized, double-blind, multicenter phase 3 study evaluating the efficacy and safety of niraparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, as first-line maintenance therapy in Chinese patients with extensive-stage SCLC (ES-SCLC).